Benjamin F. Edwards & Company’s Collegium Pharmaceutical COLL Stock Holding History

Benjamin F. Edwards & Company’s Portfolio COLL Stock Details COLL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-6,041	Closed	-$69K	–	1872
2019 Q3	$69K	Buy	6,041 +1,500	+33%	+$17.1K	0.01%	836
2019 Q2	$60K	Hold	4,541	–	–	0.01%	849
2019 Q1	$69K	Sell	4,541 -1,459	-24%	-$23.4K	0.01%	781
2018 Q4	$103K	Hold	6,000	–	–	0.01%	659
2018 Q3	$88K	Buy	6,000 +4,500	+300%	+$79.8K	0.01%	714
2018 Q2	$36K	Sell	1,500 -7,000	-82%	-$172K	﹤0.01%	934
2018 Q1	$217K	Buy	8,500 +1,000	+13%	+$23.8K	0.02%	486
2017 Q4	$138K	Buy	7,500 +3,500	+88%	+$50.1K	0.01%	576
2017 Q3	$42K	Buy	+4,000	New	+$44.1K	0.01%	811

Other funds holding COLL

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Benjamin F. Edwards & Company's COLL Position: Q4 2019 in Review

Benjamin F. Edwards & Company sold out of Collegium Pharmaceutical (COLL) in Q4 2019, closing a stake of 6,041 shares — an estimated $69K sold.

Benjamin F. Edwards & Company first reported a position in COLL in Q3 2017 and held it in 9 quarters. The position peaked at $217K in Q1 2018. 138 funds tracked by Wall St. Rank hold COLL as of Q4 2019.

Benjamin F. Edwards & Company reported no remaining Collegium Pharmaceutical position as of Q4 2019 after selling out during the quarter.
Benjamin F. Edwards & Company sold 6,041 Collegium Pharmaceutical shares in Q4 2019, an estimated $69K.
Benjamin F. Edwards & Company first reported a position in Collegium Pharmaceutical in Q3 2017 and held it in 9 quarters.
Benjamin F. Edwards & Company's Collegium Pharmaceutical position peaked at $217K in Q1 2018.
138 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q4 2019.

Based on Benjamin F. Edwards & Company's 13F filing for Q4 2019, filed 6 Feb 2020.